Details of the Drug

General Information of Drug (ID: DM06HG5)

Drug Name
Levomethadyl Acetate
Synonyms
LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)
Indication
Disease Entry ICD 11 Status REF
Opioid dependence 6C43.2Z Approved [1]
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
ATC Code
N07BC03: Levomethadyl Acetate
N07BC: Drugs used in opioid dependence
N07B: DRUGS USED IN ADDICTIVE DISORDERS
N07: OTHER NERVOUS SYSTEM DRUGS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 353.5
Logarithm of the Partition Coefficient (xlogp) 4.3
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.4 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 hours [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.31513 micromolar/kg/day [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.2% [2]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 8.3 L/kg [2]
Chemical Identifiers
Formula
C23H31NO2
IUPAC Name
[(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
Canonical SMILES
CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
InChI
InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
InChIKey
XBMIVRRWGCYBTQ-AVRDEDQJSA-N
Cross-matching ID
PubChem CID
15130
ChEBI ID
CHEBI:6441
CAS Number
1477-40-3
UNII
R3B637Y991
DrugBank ID
DB01227
TTD ID
D05PIZ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Agonist [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Opioid dependence
ICD Disease Classification 6C43.2Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Levomethadyl Acetate
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lofexidine. Opioid use disorder [6C43] [5]
Coadministration of a Drug Treating the Disease Different from Levomethadyl Acetate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ivosidenib. Acute myeloid leukaemia [2A60] [5]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Midostaurin. Acute myeloid leukaemia [2A60] [5]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Arn-509. Acute myeloid leukaemia [2A60] [5]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Gilteritinib. Acute myeloid leukaemia [2A60] [5]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Oliceridine. Acute pain [MG31] [5]
Mepyramine DMB4SFH Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [6]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Ivabradine. Angina pectoris [BA40] [5]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Dronedarone. Angina pectoris [BA40] [7]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [5]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Posaconazole. Aspergillosis [1F20] [5]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Levalbuterol. Asthma [CA23] [8]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Pirbuterol. Asthma [CA23] [8]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [5]
Dalfopristin DM4LTKV Major Decreased metabolism of Levomethadyl Acetate caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [9]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Retigabine. Behcet disease [4A62] [5]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Cariprazine. Bipolar disorder [6A60] [10]
Erdafitinib DMI782S Moderate Increased metabolism of Levomethadyl Acetate caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [11]
Pexidartinib DMS2J0Z Major Increased metabolism of Levomethadyl Acetate caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [12]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Eribulin. Breast cancer [2C60-2C6Y] [5]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lapatinib. Breast cancer [2C60-2C6Y] [5]
Tucatinib DMBESUA Major Decreased metabolism of Levomethadyl Acetate caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [9]
Palbociclib DMD7L94 Moderate Decreased metabolism of Levomethadyl Acetate caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [13]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Bosutinib. Breast cancer [2C60-2C6Y] [5]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [5]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Olodaterol. Chronic obstructive pulmonary disease [CA22] [8]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Vilanterol. Chronic obstructive pulmonary disease [CA22] [8]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Indacaterol. Chronic obstructive pulmonary disease [CA22] [8]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Arformoterol. Chronic obstructive pulmonary disease [CA22] [8]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Dihydrocodeine. Chronic pain [MG30] [10]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Levomethadyl Acetate and Levomilnacipran. Chronic pain [MG30] [14]
Panitumumab DMQPD1F Major Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Panitumumab. Colorectal cancer [2B91] [15]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Sevoflurane. Corneal disease [9A76-9A78] [5]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Pasireotide. Cushing syndrome [5A70] [5]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Osilodrostat. Cushing syndrome [5A70] [5]
Lumacaftor DMCLWDJ Major Increased metabolism of Levomethadyl Acetate caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [12]
MK-8228 DMOB58Q Major Decreased metabolism of Levomethadyl Acetate caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [9]
Vilazodone DM4LECQ Moderate Additive serotonergic effects by the combination of Levomethadyl Acetate and Vilazodone. Depression [6A70-6A7Z] [14]
Vortioxetine DM6F1PU Moderate Additive serotonergic effects by the combination of Levomethadyl Acetate and Vortioxetine. Depression [6A70-6A7Z] [14]
Milnacipran DMBFE74 Moderate Additive CNS depression effects by the combination of Levomethadyl Acetate and Milnacipran. Depression [6A70-6A7Z] [16]
Desvenlafaxine DMHD4PE Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Desvenlafaxine. Depression [6A70-6A7Z] [6]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Levomethadyl Acetate and OPC-34712. Depression [6A70-6A7Z] [10]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Clomipramine. Depression [6A70-6A7Z] [5]
Esketamine DMVU687 Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Esketamine. Depression [6A70-6A7Z] [6]
Mepenzolate DM8YU2F Moderate Additive antimotility effects by the combination of Levomethadyl Acetate and Mepenzolate. Digestive system disease [DE2Z] [17]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [5]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Deutetrabenazine. Dystonic disorder [8A02] [5]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ingrezza. Dystonic disorder [8A02] [5]
Cenobamate DM8KLU9 Major Increased metabolism of Levomethadyl Acetate caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Stiripentol DMMSDOY Major Decreased metabolism of Levomethadyl Acetate caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [9]
Fosphenytoin DMOX3LB Major Increased metabolism of Levomethadyl Acetate caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Rufinamide DMWE60C Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Rufinamide. Epilepsy/seizure [8A61-8A6Z] [6]
Eslicarbazepine DMZREFQ Major Increased metabolism of Levomethadyl Acetate caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Cannabidiol DM0659E Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Cannabidiol. Epileptic encephalopathy [8A62] [6]
Tazemetostat DMWP1BH Major Increased metabolism of Levomethadyl Acetate caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [12]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Solifenacin. Functional bladder disorder [GC50] [5]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Sunitinib. Gastrointestinal stromal tumour [2B5B] [5]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Levomethadyl Acetate caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [9]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [5]
Cobicistat DM6L4H2 Major Decreased metabolism of Levomethadyl Acetate caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [9]
Saquinavir DMG814N Major Decreased metabolism of Levomethadyl Acetate caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [9]
Etravirine DMGV8QU Moderate Increased metabolism of Levomethadyl Acetate caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [5]
Darunavir DMN3GCH Major Decreased metabolism of Levomethadyl Acetate caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [9]
Belladonna DM2RBWK Moderate Additive CNS depression effects by the combination of Levomethadyl Acetate and Belladonna. Infectious gastroenteritis/colitis [1A40] [19]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Suvorexant. Insomnia [7A00-7A0Z] [10]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Amobarbital. Insomnia [7A00-7A0Z] [10]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Tasimelteon. Insomnia [7A00-7A0Z] [10]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Levomethadyl Acetate and ITI-007. Insomnia [7A00-7A0Z] [10]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Quazepam. Insomnia [7A00-7A0Z] [10]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [10]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Crizotinib. Lung cancer [2C25] [5]
Brigatinib DM7W94S Moderate Increased metabolism of Levomethadyl Acetate caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [21]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ceritinib. Lung cancer [2C25] [5]
PF-06463922 DMKM7EW Major Increased metabolism of Levomethadyl Acetate caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [12]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Osimertinib. Lung cancer [2C25] [5]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Selpercatinib. Lung cancer [2C25] [5]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lumefantrine. Malaria [1F40-1F45] [5]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Hydroxychloroquine. Malaria [1F40-1F45] [5]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [5]
Idelalisib DM602WT Major Decreased metabolism of Levomethadyl Acetate caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [9]
IPI-145 DMWA24P Major Decreased metabolism of Levomethadyl Acetate caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [9]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Vemurafenib. Melanoma [2C30] [5]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and LGX818. Melanoma [2C30] [5]
Dabrafenib DMX6OE3 Major Increased metabolism of Levomethadyl Acetate caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [12]
Danazol DML8KTN Major Decreased metabolism of Levomethadyl Acetate caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [9]
Allopregnanolone DMNLHAC Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [6]
Exjade DMHPRWG Moderate Decreased metabolism of Levomethadyl Acetate caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [22]
Flibanserin DM70DTN Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Flibanserin. Mood disorder [6A60-6E23] [6]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Panobinostat. Multiple myeloma [2A83] [5]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Siponimod. Multiple sclerosis [8A40] [23]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Fingolimod. Multiple sclerosis [8A40] [7]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ozanimod. Multiple sclerosis [8A40] [5]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Romidepsin. Mycosis fungoides [2B01] [5]
Fedratinib DM4ZBK6 Major Decreased metabolism of Levomethadyl Acetate caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [9]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Nilotinib. Myeloproliferative neoplasm [2A20] [5]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Dasatinib. Myeloproliferative neoplasm [2A20] [5]
Prasugrel DM7MT6E Moderate Altered absorption of Levomethadyl Acetate due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [23]
Netupitant DMEKAYI Major Decreased metabolism of Levomethadyl Acetate caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [9]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Levomethadyl Acetate when combined with Metoclopramide. Nausea/vomiting [MD90] [24]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Entrectinib. Non-small cell lung cancer [2C25] [5]
Polythiazide DMCH80F Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Polythiazide. Oedema [MG29] [15]
Olaparib DM8QB1D Moderate Decreased metabolism of Levomethadyl Acetate caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [23]
Rucaparib DM9PVX8 Major Decreased metabolism of Levomethadyl Acetate caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [9]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Triclabendazole. Parasitic worm infestation [1F90] [5]
Abametapir DM2RX0I Moderate Decreased metabolism of Levomethadyl Acetate caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [25]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Levomethadyl Acetate and Methylscopolamine. Peptic ulcer [DA61] [19]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Macimorelin. Pituitary gland disorder [5A60-5A61] [26]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lefamulin. Pneumonia [CA40] [5]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Levomethadyl Acetate caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [9]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Degarelix. Prostate cancer [2C82] [5]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and ABIRATERONE. Prostate cancer [2C82] [5]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Enzalutamide. Prostate cancer [2C82] [5]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Levomethadyl Acetate and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [27]
Dexamethasone DMMWZET Major Increased metabolism of Levomethadyl Acetate caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [12]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Aripiprazole. Schizophrenia [6A20] [10]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Iloperidone. Schizophrenia [6A20] [5]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Paliperidone. Schizophrenia [6A20] [5]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Molindone. Schizophrenia [6A20] [10]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Levomethadyl Acetate and Thiothixene. Schizophrenia [6A20] [10]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Amisulpride. Schizophrenia [6A20] [5]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Asenapine. Schizophrenia [6A20] [5]
Voxelotor DMCS6M5 Major Decreased metabolism of Levomethadyl Acetate caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [9]
Telotristat ethyl DMDIYFZ Major Increased metabolism of Levomethadyl Acetate caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [12]
Larotrectinib DM26CQR Major Decreased metabolism of Levomethadyl Acetate caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [9]
Armodafinil DMGB035 Major Increased metabolism of Levomethadyl Acetate caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and LEE011. Solid tumour/cancer [2A00-2F9Z] [5]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [5]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [5]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Pitolisant. Somnolence [MG42] [5]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [5]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Levomethadyl Acetate caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [28]
Brilinta DMBR01X Moderate Decreased metabolism of Levomethadyl Acetate caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [5]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lenvatinib. Thyroid cancer [2D10] [5]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Cabozantinib. Thyroid cancer [2D10] [5]
Elagolix DMB2C0E Major Increased metabolism of Levomethadyl Acetate caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [12]
⏷ Show the Full List of 136 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7212).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
7 Canadian Pharmacists Association.
8 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
9 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
10 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
11 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
12 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
13 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
14 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
15 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
16 Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5. [PMID: 18171260]
17 Product Information. Lortab (acetaminophen-hydrocodone). Akorn Inc, Buffalo Grove, IL.
18 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
19 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
20 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
21 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
22 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
23 Cerner Multum, Inc. "Australian Product Information.".
24 Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21. [PMID: 3382595]
25 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
26 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
27 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
28 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.